Matrixyl 3000
Status
Cosmetic ingredient. No FDA-approved drug labeling exists. Marketed as a cosmetic ingredient and not reviewed for efficacy.
What it is
A topical peptide complex marketed for collagen support in skincare.
What published research measured
A trade preparation combining two palmitoylated peptides, generally palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7, proposed to signal for collagen synthesis and to moderate interleukin-mediated inflammation in skin. The palmitoyl chain is the functionally important part of the design, since attaching a fatty acid to a short peptide substantially improves its ability to cross the lipid-rich stratum corneum — this is the ingredient class where the delivery objection is best answered. Published studies, several supplier-associated, report improvements in wrinkle depth and skin density over twelve weeks or more. Independent replication is limited, and effect sizes are modest compared with retinoids, which have a far larger controlled evidence base for the same endpoints.
Source
HOLTKOETTER OLAF et al. 2007 — Cosmetic or dermatological topical composition contains oligopeptide derivative and apple extract, useful for treatin…
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.